Pharma biotech 'corporate name change' moves…12 companies this year

Reflecting initiatives to diversify business, changing to a holding company system, establishing group brands

Rebranding alone cannot improve corporate value…performance and business outcomes are the key

Pharmaceutical, biotech, and healthcare companies in South Korea are changing their corporate names one after another. This year alone, 12 companies have rebranded. While these changes aim to enhance brand value and clearly signal shifts in business structures and growth strategies, critics point out that without financial performance and business outcomes, they could end up as a mere “company signboard swap."

According to the Financial Supervisory Service on July 20, DA Information, an IT subsidiary of Dong-A Socio Group, announced on July 16 that it will change its corporate name to 'DAI' (pronounced D-A-I). With this rebranding, the company aims to transition from its traditional focus on IT system operation and maintenance to become an AX (AI Transformation) partner that revolutionizes corporate decision-making and workflows. DAI plans to nurture AI-driven drug discovery platforms, AI-based healthcare platforms, pharmaceutical-specific GMP solutions, and AI agents as its new growth engines.

​Aptamer Sciences held an extraordinary general meeting of shareholders on July 8 and changed its corporate name to 'Choolip & Sciences'. Its English name was also changed from 'Aptamer Sciences Inc.' to 'CHOOLIP & SCIENCES Inc.' Regarding the reason for the change, the company explained, "The corporate name was changed in accordance with changes in management objectives and business diversification strategies."

​On the same day, Woojung Bio also changed its name to 'Kolmar Biotech' at an extraordinary shareholders' meeting. This is a follow-up measure following Kolmar Holdings' push to acquire management control. Previously, in March, Woojung Bio pursued a transfer of management rights by issuing KRW 35 billion in convertible bonds to Kolmar Holdings and delegating the voting rights of the then-largest shareholder. Accordingly, the blueprint is to reflect the Kolmar Group's identity in the new corporate name and enhance its brand value.

2026 List of Corporate Name Changes for Pharma, Biotech, and Health Companies: SCM Lifescience changed its name to 'Poongjeon Pharmaceutical'. UBcare also changed its name to 'GC Medieye'. ​Neofect changed its corporate name to 'Dynamic Solution' on March 25.  Seers Technology shortened its name to 'Seers' on March 27. U2Bio changed its name to 'Jigu Holdings' on March 30. Kukjeon Pharmaceutical changed its name to 'Kukjeon' on March 31. 'Orion Atomics' to AdBiotech. 'BNC Korea Co, Ltd' to 'BNC KOREA, Inc.' ​CHA Vaccine Research Institute changed its name to 'AriBio LAB' on April 30. Solux changed its name to 'AriBio Holdings' on June 29. ​Aptamer Sciences changed its corporate name to 'Choolip & Sciences'. Woojung Bio also changed its name to 'Kolmar Biotech'

These are not the only companies changing their names. It is estimated that more than 13 pharmaceutical, biotech, and healthcare companies have changed their corporate names so far this year.

​Solux changed its name to 'AriBio Holdings' on June 29. This is part of an effort to restructure its governance and business framework around bio ahead of its upcoming merger with AriBio. Solux incorporated AriBio as a subsidiary after AriBio CEO Choung Jai-jun acquired management control of the company in 2023. It is currently pursuing an absorption merger with AriBio to pivot its LED-lighting-centered business model toward degenerative brain disease drug development and healthcare. Ahead of the merger, the company plans to align the group's governance and identity through the name change, ultimately building a holding company system that encompasses drug R&D·commercialization, and biotech investment functions.

​CHA Vaccine Research Institute changed its name to 'AriBio LAB' on April 30. This is also an extension of the plan to reorganize the biotech affiliate system around AriBio. In the process of pursuing the merger with AriBio, Solux also decided to acquire management control of Cha Vaccine Research Institute. This followed a contract signed in March, in which Solux and three other parties acquired a 33.3% stake in CHA Vaccine Research Institute, held by CHA Biotech, for KRW 23.8 billion. With this move, the goal is to reposition CHA Vaccine Research Institute as an R&D-specialized affiliate within the group and further solidify its biotech business foundation.

​Rebranding by traditional pharmaceutical firms is also noteworthy. Kukjeon Pharmaceutical changed its name to 'Kukjeon' on March 31, dropping the word 'Pharmaceutical'. The decision was made to expand its business scope beyond its existing image, which was limited to medicines, and to build a new corporate image. Based on its active pharmaceutical ingredient (API) business, Kukjeon aims to leap forward into an advanced materials company beyond pharma by nurturing electronic materials for semiconductors and displays as a new growth axis.

There are also cases where companies reverted to their previous names during the process of realigning their business identity. AdBiotech, an animal health company, changed its name to 'Orion Atomics' last September, only to revert to its original name this March, about six months later. Along with the reinstatement of its old name, the company removed numerous business objectives unrelated to its core business, such as nuclear power, energy, batteries, and virtual assets. It reorganized its business structure around its traditional livestock and bio sectors, re-clarifying its corporate identity.

​In the case of BNC Korea, it retained its Korean corporate name and standardized only its English business name. It changed 'BNC Korea Co, Ltd' to 'BNC KOREA, Inc.' This measure was taken to unify the English trade names that had been used interchangeably in practice. There are no other corporate name changes for this company within the past two years.

​In addition, U2Bio, Seers Technology, Neofect, SCM Lifescience, and UBcare have also successively changed their names this year. U2Bio changed its name to 'Jigu Holdings' on March 30. It reflected its identity as a holding company in its name in line with its physical split-off plan to transition into a venture holding company. Seers Technology shortened its name to 'Seers' on March 27 to clarify its strategic direction toward becoming a patient-centered, next-generation healthcare platform company, on the basis of its technology commercialization capabilities.

​Neofect changed its corporate name to 'Dynamic Solution' on March 25, citing an enhanced corporate image and strengthened competitiveness. SCM Lifescience changed its name to 'Poongjeon Pharmaceutical' on March 24, a move aimed at strengthening brand competitiveness and laying the groundwork for sustainable growth.

UBcare also changed its name to 'GC Medieye' on March 24. This comes six years after the company was incorporated into the Green Cross (GC) Group when GC Green Cross Healthcare (currently GC Care) acquired management control for 208.8 billion KRW in 2020. This name change is interpreted as a move to bring the GC Group's identity to the forefront and emphasize its direction to transcend its existing electronic medical record (EMR) business and leap forward as an AI-based digital healthcare company.

​Changing a corporate name is an effective tool for companies to communicate their altered business structures and mid- to long-term strategies to the market while enhancing brand value. In particular, when an existing corporate name is tied to a specific technology or traditional manufacturing sector, changing it to a more scalable name can signal a strategic pivot toward becoming a comprehensive bio-healthcare enterprise externally.

​However, changing a corporate name does not alter a company's own competitiveness. Experts point out that even if a company changes its name as part of business diversification and entry into new markets, the move could be a mere "signboard change" that only inflates expectations if revenue expansion, profitability improvements, and R&D achievements do not follow. Given that there are already numerous cases where performance improvements or new business outcomes failed to materialize despite a name change, some argue that strengthening the competitiveness of the core business must take priority over a new name.